Topical ruxolitinib improves atopic dermatitis
A topical formulation of the JAK1/2 inhibitor ruxolitinib (1.5%) administered twice daily led to dose-dependent improvement of 71.6% in atopic dermatitis in a phase II randomized trial presented at the European Academy of Dermatology and Venereology congress in Paris.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies